Back to search results

Pilot Study: Diet and Chemotherapy for Cancer

This study is looking at whether a special diet can help cancer patients undergoing chemotherapy. Researchers want to see if combining intermittent caloric restriction (eating less at certain times) and a plant-based diet is practical and safe alongside standard chemotherapy. They also hope this diet might reduce side effects and improve how well chemotherapy works against cancer. You may be able to join if you are an adult (18 or older) with cancer who is eligible for chemotherapy and has a life expectancy of at least 6 months, along with healthy blood, kidney, and liver function. The study aims to understand if this dietary approach is feasible over 12 months.

Study design
This is a pilot study, meaning it's a small-scale test, planning to enroll 30 participants. It is an interventional study, where participants will receive a specific dietary intervention.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months to assess the feasibility of the dietary intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05359848

A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy

Recruiting
NAAges 18+InterventionalTreatment
State University of New York at Buffalo
~30 participants
Updated 2026-02-20 on ClinicalTrials.gov
What's tested:Diet

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The feasibility of intermittent caloric restriction plus a plant-based diet in cancer patients receiving chemotherapy
Measured over 12 Months
+2 more outcomes measured

Conditions

Medical Oncology
Integrative Oncology
Medical Nutrition Therapy

Explore related trials

Solid Neoplasm

NCT05359848

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University at Buffalo / Great Lakes Cancer Care

    Buffalo, New Yorkstudy coordinator listed

    Recruiting

  • University at Buffalo / Great Lakes Cancer Care

    Buffalo, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Ashlee Lang, MPH
[email protected]
716-860-0267
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

• Histologically documented, cancer patients who are eligible to receive cytotoxic chemotherapy.
Life expectancy of at least 6 months
Adults ≥ 18 years of age
Adequate hematologic, renal, and liver function as evidenced by the following:
White blood cell (WBC) ≥ 2,500 cells/μL
Absolute neutrophil count (ANC) ≥ 1,000 cells/μL
Platelet Count ≥ 100,000 cells/μL
Hemoglobin (HgB) ≥ 9.0 g/dL
Creatinine ≤ 2.0 mg/dL
Total bilirubin ≤ 2 x upper limit of normal (ULN)
Aspartate aminotransaminase (AST, SGOT) ≤ 2.5 x ULN
Alanine aminotransaminase (ALT, SGPT) ≤ 2.5 x ULN

Exclusion

• Eastern Cooperative Oncology Group (ECOG) performance status 2 or higher
Treatment with any of the following medications or interventions within 28 days of registration:
Systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable.
High dose calcitriol \[1,25(OH)2VitD\] (i.e., \> 7.0 μg/week)
Any infection requiring parenteral antibiotic therapy or causing fever (temperature \> 100.5°F or 38.1°C) within 1 week prior to registration
A known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT/MRI imaging
Any medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives

What this trial measures

  • The feasibility of intermittent caloric restriction plus a plant-based diet in cancer patients receiving chemotherapy12 Months

    enrollment rate

  • The feasibility of intermittent caloric restriction plus a plant-based diet in cancer patients receiving chemotherapy12 Months

    drop-out rate

  • The feasibility of intermittent caloric restriction plus a plant-based diet in cancer patients receiving chemotherapy12 Months

    compliance with diet measured by self-reports